title: Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.
abstract: Tolerizing mechanisms within the host and tumor microenvironment inhibit T-cell effector functions that can control cancer. These mechanisms blunt adoptive immunotherapy with infused T-cells due to a complex array of signals that determine T-cell tolerance, survival, or deletion. Ligation of the negative regulatory receptors CTLA4, PD-1(PDCD1), or LAG3 on T-cells normally hinders their response to antigen through nonredundant biochemical processes that interfere with stimulatory pathways. In this study, we used an established mouse model of T-cell tolerance to define the roles of these inhibitory receptors in regulating CD8(+) T-cell tolerance during adoptive immunotherapy to treat leukemia. Blocking CTLA4 and PD-1 in vivo combined to promote survival of transferred T-cells despite powerful deletional signals that mediate Bim (BCL2L11)-dependent apoptosis. However, this dual blockade was not optimal for stimulating effector function by responding T-cells, which required the additional blockade of LAG3 to induce full expansion and allow the acquisition of robust cytolytic activity. Thus, the cooperation of multiple distinct regulatory pathways was needed for the survival and effector differentiation of adoptively transferred tumor-reactive CD8(+) T-cells. Our work defines the immune escape pathways in which simultaneous blockade could yield durable immunotherapeutic responses that can eradicate disseminated leukemia.
authors.affiliation: Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri 63104, USA.
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Berrien-Elliott
authors.forename: Stephanie R
authors.initials: SR
authors.lastname: Jackson
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Meyer
authors.forename: Craig J
authors.initials: CJ
authors.lastname: Rouskey
authors.forename: Thanh-Long M
authors.initials: TL
authors.lastname: Nguyen
authors.forename: Hideo
authors.initials: H
authors.lastname: Yagita
authors.forename: Philip D
authors.initials: PD
authors.lastname: Greenberg
authors.forename: Richard J
authors.initials: RJ
authors.lastname: DiPaolo
authors.forename: Ryan M
authors.initials: RM
authors.lastname: Teague
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D007108:Immune Tolerance; D016219:Immunotherapy, Adoptive; D051379:Mice; D008822:Mice, Transgenic; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D019139:Tumor Escape; D000093322:Lymphocyte Activation Gene 3 Protein
chemical_list: D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor; D000093322:Lymphocyte Activation Gene 3 Protein; C000720327:Lag3 protein, mouse